Allogene Therapeutics is a clinical-stage biotechnology enterprise pioneering the development of allogeneic (off-the-shelf) CAR T cell immunotherapy products designed to treat various blood cancers and solid tumors. By utilizing gene-edited healthy donor cells rather than a patient's own cells, the company aims to make cell therapy treatments faster, more scalable, and universally accessible for cancer patients.